The RDS message may be created by the pharmacy/treatment application for each instance of dispensing a drug or treatment to fill an existing order or orders. In the most common case, the RDS messages would be routed to a Nursing application or to some clinical application, which needs the data about drugs dispensed or treatments given. As a site-specific variant, the original order segments (RXO, RXE and their associated RXR/RXCs) may be sent optionally (for comparison).
The ORC must have the filler order number and the order control code RE. The RXE and associated RXCs may be present if the receiving application needs any of their data. The RXD carries the dispense data for a given issuance of medication: thus it may describe a single dose, a half-day dose, a daily dose, a refill of a prescription, etc. The RXD is not a complete record of an order. Use the RXO and RXE segments if a complete order is needed. It is a record from the pharmacy or treatment supplier to the Nursing application (or other) with drug/treatment dispense and administration instructions.
The FT1 segment is optional and repeating in order to accommodate multiple charge, benefit and pricing situations. Example use cases demonstrating zero, one and two FT1 segments follow:
In the case where the RDS message represents a dispense event that is in process (i.e., has not been received by the patient), the financial transactions associated with the dispense do not yet exist. Until the financial transactions associated with the dispense event have been completed, no FT1 segment may exist in the message.
In the case where the RDS message represents a dispense event that has been received by the patient, and thus all financial transactions have been completed, the RDS message may contain one or more FT1 segments. Examples of single and multiple FT1 segments follow.
Payment for the dispense event completed by a single payor:
MSH|^&~\|Pharm|GenHosp|CIS|GenHosp|2006082911150700||RDS^O13^RDS_O13|...
PID|...
ORC|RE|...
RXD|1|00310-0131-10^LISINOPRIL 10MG TABLET^NDC|200607150830|100|TAB|...
FT1|1|||200607151035||PY|00310-0131-10^LISINOPRIL 10MG TABLET^NDC|||100|125.43&USD|...
Payment for the dispense event involves multiple payment sources:
MSH|^&~\|Pharm|GenHosp|CIS|GenHosp|2006082213000700||RDS^O13^RDS_O13|...
PID|...
ORC|RE|...
RXD|1|00340-0241-10^VERAPAMIL 120MG TABLET^NDC|200607200940|100|TAB|...
FT1|1|||200607211055||CD|00340024110^VERAPAMIL 120MG TABLET ^NDC|||100|55.43&USD|...
FT1|2|||200607211055||CP|00340024110^VERAPAMIL 120MG TABLET ^NDC|||100|5.00&USD|...
Note: The use of RDS with the trigger of O01 and RRD with the trigger O02 is maintained for backward compatibility as of v 2.4 and is withdrawn as of v 2.7.
Segment | Cardinality | Implement | Status |
---|---|---|---|
RDS^O13^RDS_O13 | |||
MSH Message Header |
[1..1] | SHALL | |
ARV Access Restriction |
|||
SFT Software Segment |
|||
UAC User Authentication Credential Segment |
[0..1] | ||
NTE Notes and Comments |
|||
PATIENT | [0..1] | ||
PID Patient Identification |
[1..1] | SHALL | |
PD1 Patient Additional Demographic |
[1..1] | SHALL | |
PRT Participation Information |
|||
ARV Access Restriction |
B | ||
NTE Notes and Comments |
|||
AL1 Patient Allergy Information |
|||
PATIENT_VISIT | [0..1] | ||
PV1 Patient Visit |
[1..1] | SHALL | |
PV2 Patient Visit - Additional Information |
[0..1] | ||
PRT Participation Information |
|||
ARV Access Restriction |
B | ||
ORDER | [1..*] | SHALL | |
ORC Common Order |
[1..1] | SHALL | |
PRT Participation Information |
|||
TIMING | |||
TQ1 Timing/Quantity |
[1..1] | SHALL | |
TQ2 Timing/Quantity Relationship |
|||
ORDER_DETAIL | [0..1] | ||
RXO Pharmacy/Treatment Order |
[1..1] | SHALL | |
PRT Participation Information |
|||
ORDER_DETAIL_SUPPLEMENT | [0..1] | ||
NTE Notes and Comments |
[1..*] | SHALL | |
RXR Pharmacy/Treatment Route |
[1..*] | SHALL | |
COMPONENT | |||
RXC Pharmacy/Treatment Component Order |
[1..1] | SHALL | |
NTE Notes and Comments |
|||
ENCODING | [0..1] | ||
RXE Pharmacy/Treatment Encoded Order |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
TIMING_ENCODED | [1..*] | SHALL | |
TQ1 Timing/Quantity |
[1..1] | SHALL | |
TQ2 Timing/Quantity Relationship |
|||
RXR Pharmacy/Treatment Route |
[1..*] | SHALL | |
RXC Pharmacy/Treatment Component Order |
|||
RXD Pharmacy/Treatment Dispense |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
RXR Pharmacy/Treatment Route |
[1..*] | SHALL | |
RXC Pharmacy/Treatment Component Order |
|||
CDO Cumulative Dosage |
|||
OBSERVATION | |||
OBX Observation/Result |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
FT1 Financial Transaction |
MSH-15 | MSH-16 | Immediate ACK | Application Ack |
---|---|---|---|
Blank | Blank | - | RRD^O14^RRD_O14 |
NE | NE | - | - |
NE | AL, SU, ER | - | RRD^O14^RRD_O14 |
AL, SU, ER | AL, SU, ER | ACK^O13^ACK | RRD^O14^RRD_O14 |